Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mondelēz International reported for 3 months of 2023

4/28/23 MDLZ

Gilead reports on 3 months of 2023

4/28/23 GILD

Amazon reported for 3 months of 2023

4/28/23 AMZN

Intel reported for 3 months of 2023

4/28/23 INTC

EL5-Energo in Q1 decreased energy generation by 6.7%

4/28/23 ELFV

European Electrotechnics reported for 2022 by IFRS

4/27/23 EELT

ТNS Energo Rostov-on-Don reported for 3 months of 2023 according to RAS

4/27/23 RTSB

Plant of ecological equipment and eco-food DIIOD reported for 2022 by IFRS

4/27/23 DIOD

Plant of ecological equipment and eco-food DIIOD reported for 2022 by IFRS

4/27/23 DIOD

Arsagera reported for 2022 according to IFRS

4/27/23 ARSA